Two doses of the vaccine produced by Janssen, the pharmaceutical arm of Johnson & Johnson (J&J), reduced the risk of hospitalization for complications related to the Ômicron variant of the coronavirus by 85%, as shown by preliminary results of a study conducted by the Medical Research Council of Africa southern.
The decrease in the need for hospitalization occurred among patients who took the booster injection one to two months after the first. In cases where the interval between doses was up to two weeks, the risk reduction dropped to 63%. When the difference was between 14 and 27 days, the drop was 84%, according to tests.
The researchers analyzed the effectiveness of the immunizer in 69,092 healthcare professionals who were vaccinated between November 15 and December 20, 2021, when Ômicron became the dominant variant in South Africa.
The post Two doses of the J&J vaccine reduce the risk of hospitalization for Ômicron, says study first appeared in ISTOÉ MONEY.
#doses #JJs #vaccine #reduce #risk #hospitalization #Ômicron #study #ISTOÉ #MONEY